EUVIMEDEUVIMED entdecken
Crossref

Real-world evaluation of first-line treatment of extensive-stage small-cell lung cancer with atezolizumab plus platinum/etoposide: a focus on patients with brain metastasis

Hanxiao Chen, Xiangjuan Ma, Jie Liu, Yu Yang, Yanhui He, Yong Fang, Liping Wang, Jian Fang, Jun Zhao, Minglei Zhuo

Clinical and Translational Oncology · 2024

DOI: 10.1007/s12094-024-03387-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Hanxiao Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department I of Thoracic Oncology, Peking University Can…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Etoposide, Small Cell Lung Carcinoma, Brain Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: National Natural Science Foundation of China, The Capital's Funds for Health Improvement and Research, The Beijing Municipal Administration of Hospitals Incubating Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedEtoposideSmall Cell Lung CarcinomaBrain NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsLung NeoplasmsHumansMaleRetrospective StudiesFemaleMiddle AgedAgedAdultProgression-Free SurvivalKaplan-Meier EstimateCisplatinSurvival RateAged, 80 and over

Stichwörter der Autor:innen

Brain metastasesExtensive-stage SCLCImmunotherapyReal-world study

Substanzen

atezolizumabAntibodies, Monoclonal, HumanizedEtoposideCisplatin

Autor:innen und Institutionen

  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department I of Thoracic Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department II of Thoracic Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
  • Cancer Center, Shandong Public Health Clinical Center, Public Health Clinical Center Affiliated to Shandong University, Shandong University, Jinan, China.
  • Department of Oncology, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China.
  • Department of Oncology, Sir Run Run Shaw Hospital Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Oncology, Baotou Cancer Hospital, Baotou, China.

Förderung

  • National Natural Science Foundation of China
  • The Capital's Funds for Health Improvement and Research
  • The Beijing Municipal Administration of Hospitals Incubating Program
  • Wu Jieping Medical Foundation
  • Clinical Research Fund for Distinguished Young Scholars of Beijing Cancer Hospital
  • Guangzhou Life oasis public service center Research and exchange program in the field of health

Zitieren

APA

Chen, H., Ma, X., Liu, J., Yang, Y., He, Y., Fang, Y., Wang, L., Fang, J., Zhao, J., & Zhuo, M. (2024). Real-world evaluation of first-line treatment of extensive-stage small-cell lung cancer with atezolizumab plus platinum/etoposide: a focus on patients with brain metastasis. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03387-7

Vancouver

Chen H, Ma X, Liu J, Yang Y, He Y, Fang Y, et al. Real-world evaluation of first-line treatment of extensive-stage small-cell lung cancer with atezolizumab plus platinum/etoposide: a focus on patients with brain metastasis. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03387-7

BibTeX
@article{Chen2024,
  author = {Chen, Hanxiao and Ma, Xiangjuan and Liu, Jie and Yang, Yu and He, Yanhui and Fang, Yong and Wang, Liping and Fang, Jian and Zhao, Jun and Zhuo, Minglei},
  title = {Real-world evaluation of first-line treatment of extensive-stage small-cell lung cancer with atezolizumab plus platinum/etoposide: a focus on patients with brain metastasis},
  journal = {Clinical and Translational Oncology},
  year = {2024},
  doi = {10.1007/s12094-024-03387-7}
}
Kostenlos starten →